Compare Innovative Industrial Properties Inc (IIPR) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Innovative Industrial Properties Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Innovative Industrial Properties Inc trades at $57.85 (market cap $1.67B), while Vertex Pharmaceuticals Incorporated trades at $525.61 (market cap $134.25B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 80.4× Innovative Industrial Properties Inc's market cap, and Innovative Industrial Properties Inc pays a 13.18% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| IIPR | VRTX | |
|---|---|---|
Market Cap | $1.67B | $134.25B |
Sector | Real Estate | Health |
52-Week High | $64.67 | $529.65 |
52-Week Low | $44.58 | $376.62 |
Enterprise Value | $2.21B | $128.37B |
Dividend Yield | 13.18% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Innovative Industrial Properties (IIPR) trades at $57.84, up 0.63% on the day, with a bearish technical signal and neutral oscillators. The company reported Q2 2026 revenue of $63.3 million and FFO of $1.83 per share, beating estimates. Financials show strong gross margins of 88.35% but declining revenue from $266 million in 2025 to $264 million in 2026. Recent news highlights institutional buying and dividend sustainability debates amid tenant distress concerns.
Outlook remains mixed with a discounted P/E of 13.05 and high dividend yield offering value, but risks include revenue contraction, tenant diversification issues, and bearish technical trends. Analyst consensus is cautious with 36% buy ratings. The stock presents income appeal but requires monitoring of operational execution and cannabis sector volatility.
Vertex Pharmaceuticals (VRTX) trades at $526.33, up 0.46% on the day, with a bullish technical outlook supported by moving averages. The stock shows strong fundamentals with 2025 revenue of $12.0B and net income of $3.95B, though recent Q2 2026 earnings slightly missed estimates. Analyst sentiment remains positive with an 83.9% buy rating and a $534.25 consensus price target, while news highlights raised 2026 sales guidance driven by cystic fibrosis drug strength and newer product launches.
The outlook for VRTX is favorable given robust revenue growth, high profitability margins, and raised full-year guidance. Key opportunities include diversification beyond cystic fibrosis with newer products, but risks involve earnings volatility, competitive pressures, and execution on pipeline developments. The stock's valuation at a P/E of 30.85 requires sustained growth to justify further upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Innovative Industrial Properties Inc
Innovative Industrial Properties Inc is a real estate investment trust engaged in the acquisition, ownership, and management of specialized industrial properties leased to state-licensed operators for their regulated medical-use cannabis facilities. It conducts its business through a traditional umbrella partnership real estate investment trust, or UPREIT structure, in which properties are owned by Operating Partnership, directly or through subsidiaries. Its property portfolio is spread across the United States.
Read more on IIPR →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
